tiprankstipranks
Globus Medical (MX:GMED)
:GMED
Mexico Market
GMED
Globus Medical
RESEARCH TOOLSreports

Globus Medical (GMED) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

GMED Analyst Ratings

Strong Buy
12Ratings
Strong Buy
9 Buy
3 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Globus
Medical
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GMED Stock 12 Month Forecast

Average Price Target

$1,804.52
▲(29.78% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Globus Medical in the last 3 months. The average price target is $1,804.52 with a high forecast of $2,134.19 and a low forecast of $1,388.09. The average price target represents a 29.78% change from the last price of $1,390.45.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"990":"$990","2135":"$2,135","1276.25":"$1,276.3","1562.5":"$1,562.5","1848.75":"$1,848.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2134.19395182,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.13K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1804.5217153599997,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.80K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1388.0936272,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.39K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[990,1276.25,1562.5,1848.75,2135],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1390.45,1447.6610732169231,1504.8721464338462,1562.0832196507693,1619.2942928676923,1676.5053660846154,1733.7164393015387,1790.9275125184618,1848.1385857353848,1905.349658952308,1962.560732169231,2019.771805386154,2076.982878603077,{"y":2134.19395182,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1390.45,1422.3016704123077,1454.1533408246153,1486.005011236923,1517.8566816492307,1549.7083520615383,1581.560022473846,1613.4116928861538,1645.2633632984614,1677.115033710769,1708.9667041230766,1740.8183745353845,1772.670044947692,{"y":1804.5217153599997,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1390.45,1390.268740553846,1390.0874811076924,1389.9062216615384,1389.7249622153847,1389.5437027692308,1389.3624433230768,1389.1811838769231,1388.9999244307692,1388.8186649846152,1388.6374055384615,1388.4561460923076,1388.2748866461538,{"y":1388.0936272,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":991.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1151.85,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1080,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1067,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1670,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1557.69,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1650,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1618.62,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1618.62,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1618.62,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1463.25,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1465,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1390.45,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$2,134Average Price Target$1,805Lowest Price Target$1,388
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on MX:GMED
Unknown Analyst
UBS
Not Ranked
UBS
$1,422.8
Hold
2.33%
Upside
Initiated
07/28/26
Globus Medical initiated with a Neutral at UBSGlobus Medical initiated with a Neutral at UBS
Truist Financial Analyst forecast on MX:GMED
Richard Newitter
Truist Financial
Truist Financial
$1,995.38→$1,735.12
Buy
24.79%
Upside
Reiterated
07/16/26
Globus Medical price target lowered to $100 from $115 at TruistGlobus Medical price target lowered to $100 from $115 at Truist
RBC Capital Analyst forecast on MX:GMED
Shagun Singh Chadha
RBC Capital
RBC Capital
$2,082.14→$1,995.38
Buy
43.51%
Upside
Reiterated
07/13/26
Globus Medical price target lowered to $115 from $120 at RBC CapitalGlobus Medical price target lowered to $115 from $120 at RBC Capital
BTIG Analyst forecast on MX:GMED
Ryan Zimmerman
BTIG
BTIG
―
Hold
―
Reiterated
07/10/26
BTIG Keeps Their Hold Rating on Globus Medical (GMED)
BMO Capital Analyst forecast on MX:GMED
Vik Chopra
BMO Capital
BMO Capital
$1,631.01
Buy
17.30%
Upside
Initiated
07/09/26
Globus Medical initiated with an Outperform at BMO CapitalGlobus Medical initiated with an Outperform at BMO Capital
Stifel Nicolaus Analyst forecast on MX:GMED
Thomas Stephan
Stifel Nicolaus
Stifel Nicolaus
$1,648.36→$1,388.09
Hold
-0.17%
Downside
Assigned
07/08/26
Globus Medical price target lowered to $80 from $95 at StifelGlobus Medical price target lowered to $80 from $95 at Stifel
TD Cowen Analyst forecast on MX:GMED
Mathew Blackman
TD Cowen
TD Cowen
$1,995.38
Buy
43.51%
Upside
Reiterated
06/22/26
Globus Medical Buy Rating Reiterated on Underappreciated Growth and Earnings Power; Price Target Maintained at $115
Piper Sandler Analyst forecast on MX:GMED
Matthew O'Brien
Piper Sandler
Piper Sandler
$1,995.38→$1,735.12
Buy
24.79%
Upside
Reiterated
06/15/26
Globus Medical price target lowered to $100 from $115 at Piper SandlerGlobus Medical price target lowered to $100 from $115 at Piper Sandler
Barclays Analyst forecast on MX:GMED
Matt Miksic
Barclays
Barclays
$2,134.19
Buy
53.49%
Upside
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (NYSE: HIMS), BridgeBio Pharma (NASDAQ: BBIO) and Globus Medical (NYSE: GMED)
Canaccord Genuity Analyst forecast on MX:GMED
Caitlin Roberts
Canaccord Genuity
Canaccord Genuity
$1,995.38
Buy
43.51%
Upside
Reiterated
05/08/26
Canaccord Genuity Sticks to Their Buy Rating for Globus Medical (GMED)
Wells Fargo Analyst forecast on MX:GMED
Larry Biegelsen
Wells Fargo
Wells Fargo
$1,804.52→$1,787.17
Buy
28.53%
Upside
Reiterated
05/08/26
Wells Fargo Reaffirms Their Buy Rating on Globus Medical (GMED)
Needham Analyst forecast on MX:GMED
David Saxon
Needham
Needham
$1,978.03→$2,030.09
Buy
46.00%
Upside
Reiterated
05/08/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Bank of America Securities Analyst forecast on MX:GMED
Travis Steed
Bank of America Securities
Bank of America Securities
$1,839.22
Buy
32.28%
Upside
Reiterated
02/25/26
Bank of America Securities Sticks to Its Buy Rating for Globus Medical (GMED)
Jefferies Analyst forecast on MX:GMED
Matthew Taylor
Jefferies
Jefferies
$1,821.87→$1,995.38
Buy
43.51%
Upside
Reiterated
01/08/26
Jefferies Sticks to Its Buy Rating for Globus Medical (GMED)
Freedom Capital Markets Analyst forecast on MX:GMED
Keith Hinton
Freedom Capital Markets
Freedom Capital Markets
$1,509.55
Hold
8.57%
Upside
Initiated
12/16/25
Analysts Offer Insights on Healthcare Companies: Novan (NASDAQ: NOVN) and Globus Medical (NYSE: GMED)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on MX:GMED
Unknown Analyst
UBS
Not Ranked
UBS
$1,422.8
Hold
2.33%
Upside
Initiated
07/28/26
Globus Medical initiated with a Neutral at UBSGlobus Medical initiated with a Neutral at UBS
Truist Financial Analyst forecast on MX:GMED
Richard Newitter
Truist Financial
Truist Financial
$1,995.38→$1,735.12
Buy
24.79%
Upside
Reiterated
07/16/26
Globus Medical price target lowered to $100 from $115 at TruistGlobus Medical price target lowered to $100 from $115 at Truist
RBC Capital Analyst forecast on MX:GMED
Shagun Singh Chadha
RBC Capital
RBC Capital
$2,082.14→$1,995.38
Buy
43.51%
Upside
Reiterated
07/13/26
Globus Medical price target lowered to $115 from $120 at RBC CapitalGlobus Medical price target lowered to $115 from $120 at RBC Capital
BTIG Analyst forecast on MX:GMED
Ryan Zimmerman
BTIG
BTIG
―
Hold
―
Reiterated
07/10/26
BTIG Keeps Their Hold Rating on Globus Medical (GMED)
BMO Capital Analyst forecast on MX:GMED
Vik Chopra
BMO Capital
BMO Capital
$1,631.01
Buy
17.30%
Upside
Initiated
07/09/26
Globus Medical initiated with an Outperform at BMO CapitalGlobus Medical initiated with an Outperform at BMO Capital
Stifel Nicolaus Analyst forecast on MX:GMED
Thomas Stephan
Stifel Nicolaus
Stifel Nicolaus
$1,648.36→$1,388.09
Hold
-0.17%
Downside
Assigned
07/08/26
Globus Medical price target lowered to $80 from $95 at StifelGlobus Medical price target lowered to $80 from $95 at Stifel
TD Cowen Analyst forecast on MX:GMED
Mathew Blackman
TD Cowen
TD Cowen
$1,995.38
Buy
43.51%
Upside
Reiterated
06/22/26
Globus Medical Buy Rating Reiterated on Underappreciated Growth and Earnings Power; Price Target Maintained at $115
Piper Sandler Analyst forecast on MX:GMED
Matthew O'Brien
Piper Sandler
Piper Sandler
$1,995.38→$1,735.12
Buy
24.79%
Upside
Reiterated
06/15/26
Globus Medical price target lowered to $100 from $115 at Piper SandlerGlobus Medical price target lowered to $100 from $115 at Piper Sandler
Barclays Analyst forecast on MX:GMED
Matt Miksic
Barclays
Barclays
$2,134.19
Buy
53.49%
Upside
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (NYSE: HIMS), BridgeBio Pharma (NASDAQ: BBIO) and Globus Medical (NYSE: GMED)
Canaccord Genuity Analyst forecast on MX:GMED
Caitlin Roberts
Canaccord Genuity
Canaccord Genuity
$1,995.38
Buy
43.51%
Upside
Reiterated
05/08/26
Canaccord Genuity Sticks to Their Buy Rating for Globus Medical (GMED)
Wells Fargo Analyst forecast on MX:GMED
Larry Biegelsen
Wells Fargo
Wells Fargo
$1,804.52→$1,787.17
Buy
28.53%
Upside
Reiterated
05/08/26
Wells Fargo Reaffirms Their Buy Rating on Globus Medical (GMED)
Needham Analyst forecast on MX:GMED
David Saxon
Needham
Needham
$1,978.03→$2,030.09
Buy
46.00%
Upside
Reiterated
05/08/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Bank of America Securities Analyst forecast on MX:GMED
Travis Steed
Bank of America Securities
Bank of America Securities
$1,839.22
Buy
32.28%
Upside
Reiterated
02/25/26
Bank of America Securities Sticks to Its Buy Rating for Globus Medical (GMED)
Jefferies Analyst forecast on MX:GMED
Matthew Taylor
Jefferies
Jefferies
$1,821.87→$1,995.38
Buy
43.51%
Upside
Reiterated
01/08/26
Jefferies Sticks to Its Buy Rating for Globus Medical (GMED)
Freedom Capital Markets Analyst forecast on MX:GMED
Keith Hinton
Freedom Capital Markets
Freedom Capital Markets
$1,509.55
Hold
8.57%
Upside
Initiated
12/16/25
Analysts Offer Insights on Healthcare Companies: Novan (NASDAQ: NOVN) and Globus Medical (NYSE: GMED)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
ZURAZura Bio
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Globus Medical

3 Months
Jason WittesRoth MKM
Success Rate
15/23 ratings generated profit
65%
Average Return
+4.55%
Copying Jason Wittes's trades and holding each position for 3 Months would result in 65.22% of your transactions generating a profit, with an average return of +4.55% per trade.
1 Year
Matt MiksicBarclays
Success Rate
20/32 ratings generated profit
63%
Average Return
+13.00%
Copying Matt Miksic's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +13.00% per trade.
2 Years
Matt MiksicBarclays
Success Rate
24/32 ratings generated profit
75%
Average Return
+21.88%
Copying Matt Miksic's trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +21.88% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GMED Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
2
2
2
0
Buy
13
9
10
12
6
Hold
2
1
2
5
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
15
12
14
19
10
In the current month, GMED has received 6 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. GMED average Analyst price target in the past 3 months is 1,804.52.
Each month's total comprises the sum of three months' worth of ratings.

GMED Financial Forecast

GMED Earnings Forecast

Next quarter’s earnings estimate for GMED is $19.02 with a range of $18.17 to $19.73. The previous quarter’s EPS was $19.39. GMED beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.85% of the time in the same period. In the last calendar year GMED has Performed in-line its overall industry.
Next quarter’s earnings estimate for GMED is $19.02 with a range of $18.17 to $19.73. The previous quarter’s EPS was $19.39. GMED beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.85% of the time in the same period. In the last calendar year GMED has Performed in-line its overall industry.

GMED Sales Forecast

Next quarter’s sales forecast for GMED is $13.55B with a range of $13.39B to $13.67B. The previous quarter’s sales results were $13.15B. GMED beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.33% of the time in the same period. In the last calendar year GMED has Performed in-line its overall industry.
Next quarter’s sales forecast for GMED is $13.55B with a range of $13.39B to $13.67B. The previous quarter’s sales results were $13.15B. GMED beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.33% of the time in the same period. In the last calendar year GMED has Performed in-line its overall industry.

GMED Stock Forecast FAQ

What is MX:GMED’s average 12-month price target, according to analysts?
Based on analyst ratings, Globus Medical’s 12-month average price target is 1,804.52.
    What is MX:GMED’s upside potential, based on the analysts’ average price target?
    Globus Medical has 29.78% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Globus Medical a Buy, Sell or Hold?
          Globus Medical has a consensus rating of Strong Buy, which is based on 9 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Globus Medical’s share price target?
            The average share price target for Globus Medical is 1,804.52. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $2,134.19 ,and the lowest forecast is $1,388.09. The average share price target represents 29.78% Increase from the current price of $1,390.45.
              What do analysts say about Globus Medical?
              Globus Medical’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of Globus Medical?
                To buy shares of MX:GMED, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.